MiniMed Group (MMED) SEC filings document the regulatory record of a Nasdaq-listed diabetes technology company focused on insulin delivery systems, CGMs, sensors, algorithms, and app-connected diabetes management. MiniMed's filings include annual reports, quarterly reports, proxy statements, and Form 8-K material event reports.
For MMED, the most relevant filings often relate to medical device operations and newly public company governance. Annual reports and 10-Q filings can describe business structure, risk factors, capital structure, financial results, clinical and regulatory matters, and disclosures tied to MiniMed's separation from Medtronic. Form 8-K filings have covered financial results, board appointments, executive compensation plans, officer departures, cybersecurity-related disclosures, and other material events.
Proxy statements are useful for reviewing director elections, auditor ratification, advisory compensation votes, and governance matters. Form 4 insider transaction filings can show reported purchases, sales, or equity awards by directors and officers when such filings are submitted. 10-K and 10-Q reports are especially important for understanding how MiniMed reports its diabetes technology business after becoming a public company.
AI-powered summaries can translate dense filing language into plain-English explanations, while real-time EDGAR updates can surface new MMED filings as they are released. These summaries are most useful when reviewing long annual reports, quarterly updates, proxy statements, and insider transaction disclosures.
MiniMed Group, Inc. filed an initial Form 3 for director Cundy Scott T. This filing establishes his status as a reporting person for MiniMed Group but does not list any current holdings or report any buy, sell, or other insider transactions.
MiniMed Group, Inc. outlines its diabetes-technology business and recent performance in this annual report. The company develops integrated insulin pumps, continuous glucose monitors, smart dosing algorithms, and software platforms such as CareLink to serve people with type 1 and insulin‑requiring type 2 diabetes worldwide.
Revenue reached $3.1 billion in fiscal 2026, up from $2.7 billion in 2025, but MiniMed reported net losses of $317 million and $198 million, respectively, alongside positive Adjusted EBITDA. The filing highlights strong real‑world clinical data for the MiniMed 780G automated insulin delivery system, significant international exposure, and a deep pipeline including the MiniMed Flex pump, MiniMed Fit patch pump, and the Vivera “hands‑free” dosing algorithm.
MiniMed Group, Inc. announced governance updates and its next shareholder meeting plans. The Board of Directors increased its size from nine to 11 members and appointed David Endicott and Linnea Burman as new directors, effective June 29, 2026.
Endicott will serve as a Class I director with a term expiring at the 2026 annual meeting and join the Compensation and Talent Committee. He is currently Chief Executive Officer and a director of Alcon, Inc., and has prior senior roles at several healthcare companies. The Board determined he is independent under Nasdaq, SEC and company guidelines.
Burman, a senior executive at Medtronic plc, will serve as a Class II director with a term expiring at the 2027 annual meeting. While Medtronic remains an affiliate of MiniMed, she will not receive Board compensation. MiniMed also set its 2026 annual meeting of stockholders for October 9, 2026, with an August 11, 2026 record date and mid‑July deadlines for shareholder proposals and nominations.
MiniMed Group, Inc. reported strong fourth quarter and full fiscal year 2026 revenue growth but remained unprofitable. Fourth quarter net sales were $837 million, up 15.6% as reported and 8.7% organic, driven largely by international markets and continuous glucose monitoring (CGM) products. Full-year net sales reached $3.102 billion, up 14.2% as reported and 8.0% organic, marking the first time MiniMed surpassed $3 billion in annual revenue.
Despite this top-line strength, MiniMed posted a fiscal 2026 net loss attributable to the company of $331 million, widening from $213 million a year earlier, with a basic and diluted loss per share of $1.29. Fourth quarter net loss attributable to the company was $183 million. CGM revenue grew faster than pumps, and the worldwide CGM attachment rate rose to 66% for the year, with approximately 659,000 pump users at year-end.
Looking ahead to fiscal 2027, MiniMed targets organic revenue growth of about 10%, including a modest benefit from an extra week in the fiscal year, and an adjusted EBITDA margin of about 16%. The company highlighted multiple recent product launches and regulatory clearances as key drivers for future growth.
MiniMed Group, Inc. reported that director Brett Wall, a class II member of the Board and of the Nominating and Corporate Governance Committee, has notified the company he will resign from the Board effective July 3, 2026. The company states his decision is not due to any disagreement with management or the Board, but follows his departure from a senior leadership role at Medtronic plc, MiniMed’s parent, which originally nominated him.
To fill the vacancy, Scott Cundy was appointed as a director effective July 3, 2026. He will serve as a class II director with a term expiring at the 2027 annual meeting of stockholders and will join the Nominating and Corporate Governance Committee. Cundy is a senior Medtronic executive overseeing global quality, product development, and innovation. While Medtronic remains an affiliate of MiniMed, he will receive no compensation for Board service; if that changes, his pay will align with MiniMed’s non‑employee director program.
Medtronic plc reports 252,813,348 shares beneficially owned of MiniMed Group, Inc. The Schedule 13G filing states Medtronic has sole voting and sole dispositive power over 252,813,348 shares, representing 90.0% of the class based on 280,819,988 shares outstanding as of April 11, 2026. The filing lists Medtronic Global Holdings S.C.A. as the record holder of those shares and is signed by Brian Sandstrom, VP, Chief Corporate and Securities Counsel.
MiniMed Group, Inc. reported that its parent, Medtronic plc, experienced unauthorized access to certain information technology systems. Medtronic stated it promptly contained the incident, activated incident response protocols, and engaged external cybersecurity experts to investigate and remediate.
Medtronic disclosed it has not identified any impact on its products, patient safety, customer connections, manufacturing and distribution operations, financial reporting systems, or ability to meet patient needs, and does not expect a material impact on its business or financial results. MiniMed is not aware of compromises to its own IT systems and does not currently expect a material impact on its business or financial results.
The filing also outlines potential risks if the situation worsens, including possible data release or misuse, operational and financial impacts, management distraction, litigation, strained third-party relationships, reputational harm, and regulatory scrutiny, and includes standard forward-looking statement cautions.
MiniMed Group, Inc. reported higher revenue but a larger loss as it transitioned toward standalone operations. Net sales rose to $790 million for the quarter and $2,265 million for the nine months, driven by international demand for pumps, consumables, and CGM systems.
The company posted a quarterly net loss of $111 million and a nine‑month net loss of $132 million, mainly due to higher cost of products sold, increased selling and administrative expenses, and sizable restructuring and contract termination charges, including $118 million tied to ending a third‑party manufacturing agreement.
MiniMed completed an IPO in March 2026, selling 28,000,000 shares at $20.00 per share and retaining about $309 million of net proceeds, and put in place a $500 million revolving credit facility, giving it additional liquidity as it separates from Medtronic. Subsequent to quarter‑end, FDA clearance of the MiniMed Flex insulin pump triggered a one‑time $157 million royalty‑related charge in the fourth quarter.
MiniMed Group, Inc. Chief Executive Officer Dallara Que reported a routine tax-related share disposition. On this Form 4, 4,809 shares of Common Stock were withheld by the company at $16.31 per share to cover income tax obligations tied to vesting RSUs. After this withholding, Que directly holds 616,754 shares, and the filing notes that this total includes shares to be issued upon future RSU vesting.
MiniMed Group, Inc. adopted a new Severance Pay Plan for Executives and a Change of Control Severance Plan for its named executive officers. Executives at vice president level and above become eligible for severance after certain terminations if they sign a release of claims and meet plan conditions.
For eligible terminations not tied to a change of control, each named executive officer may receive a lump-sum cash payment equal to two times annual base salary plus target bonus, and a lump-sum equal to 24 months of medical and dental COBRA premiums. Equity awards generally do not continue vesting unless the executive is retirement-eligible.
Following a change of control, each named executive officer is promised three years of employment on terms no less favorable than those in place beforehand. If they are terminated without cause or resign for good reason during that period, they may receive a pro-rated annual bonus, a lump sum equal to three times base salary plus the highest recent annual bonus, three additional years of credited retirement benefits, and three years of continued health and life insurance benefits. The plan also includes a mechanism to adjust benefits if excise taxes under Section 4999 of the Internal Revenue Code would apply.